Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It UpSeeking Alpha • 07/11/25
Harrow Appoints Mike Biega as Vice President of Investor Relations and CommunicationsBusiness Wire • 06/18/25
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa PharmaceuticalsBusiness Wire • 06/09/25
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025Business Wire • 05/05/25
Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C PatientsBusiness Wire • 04/10/25
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025Business Wire • 03/27/25
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mLBusiness Wire • 03/24/25
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue GuidanceBusiness Wire • 03/17/25
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®Business Wire • 03/11/25
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025Business Wire • 03/03/25
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025Seeking Alpha • 03/01/25